Alkaptonuria

High-Yield Core Realities:

• The Air-Oxidation Trap: Homogentisic acid is a normal intermediate in the catabolism of phenylalanine and tyrosine. When homogentisate oxidase is missing, HGA pools in blood and urine. When urine is exposed to air, the excreted HGA undergoes non-enzymatic oxidation and polymerization into a melanin-like compound, causing the urine to drop from clear to deep black.
• Ochronosis Architecture: Over decades, circulating HGA binds permanently to collagen matrices in connective tissues, tendons, and cartilage. This builds up dark blue-black pigmentation that becomes clearly visible clinically in the sclerae of the eyes and the cartilage of the ear pinnae.
• Destructive Alkaptonuric Arthropathy: The polymer deposits alter the structural integrity of joints, acting as a direct chemical toxin to chondrocytes. This triggers a progressive, severe, debilitating osteoarthritis that characteristically targets the spine (leading to intervertebral disc calcification and fusion) and large weight-bearing joints like the hips and knees, often mimicking ankylosing spondylitis but presenting later in life (typically after age 30).
• Cardiovascular Complications: Connective tissue deposition isn’t limited to joints. Accumulation occurs within vascular intimacy, leading to accelerated aortic and mitral valvular calcification and stenosis, alongside an increased risk of aortic aneurysms and coronary artery plaque formation.
• Mechanistic Management (Nitisinone): While initial treatment focuses on dietary restriction of phenylalanine and tyrosine, the therapeutic breakthrough relies on Nitisinone (Orfadin). Nitisinone inhibits 4-hydroxyphenylpyruvate dioxygenase, the upstream enzyme that generates homogentisic acid, effectively cutting off the production of the toxic polymer precursor.